Paul Hastings LLP, H-F& Co, Banai Azriel Stern and Meitar Law Offices have advised XTEND. Sichenzia Ross Ference Carmel LLP and Amit Pollak Matlon have advised...
XTEND and JFB Construction Holdings Announce $1.5 Billion Combination and Nasdaq Listing
ITT Launches $1.17 Billion Public Offering of Common Stock
Paul Hastings has advised ITT Inc. on its underwritten public offering of common stock. ITT Inc. has announced an underwritten public offering of approximately $1.17 billion,...
Aardvark Therapeutics’ $94.2 Million Initial Public Offering
Paul Hastings advised Aardvark Therapeutics on the offering. Aardvark Therapeutics, Inc. announced its approximately $94.2 million IPO on the Nasdaq Global Select Market. The offering comprises...
FACT II Acquisition Corp.’s $175 Million Initial Public Offering
Paul Hastings advised FACT II Acquisition Corp. on the offering. FACT II Acquisition Corp. announced the pricing of its initial public offering of 17,500,000 units at...
Viking Therapeutics’ $632.5 Million Common Stock Offering
Paul Hastings advised Viking Therapeutics on the offering. Viking Therapeutics, Inc. (Nasdaq: VKTX) executed its underwritten offering of $632.5 million of shares of its common stock....
Jasper Therapeutics’ $50 Million Common Stock Offering
Paul Hastings LLP advised Jasper Therapeutics, Inc., while DLA Piper advised the underwriters. Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company focused on developing novel...